The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Restoration of conformation of mutant p53
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“COTI-2 also recovers the DNA-binding properties of the p53-mutant protein.359,360”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [360]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Zhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501092z · Cited by 462
A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas
Soragni, A., Janzen, D. M., Johnson, L. M., Lindgren, A. G., Thai-Quynh Nguyen, A., Tiourin, E., Soriaga, A. B., Lu, J., Jiang, L., Faull, K. F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.002 · Cited by 341
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Mohell, N., Alfredsson, J., Fransson, Å., Uustalu, M., Byström, S., Gullbo, J., Hallberg, A., Bykov, V. J. N., Björklund, U., & Wiman, K. G. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.143 · Cited by 183
Peng, X., Zhang, M.-Q.-Z., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J. N., Arnér, E. S. J., & Wiman, K. G. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.417 · Cited by 170
An open-label phase I dose-finding study of APR-246 in hematological malignancies
Deneberg, S., Cherif, H., Lazarevic, V, Andersson, P.-O., von Euler, M., Juliusson, G., & Lehmann, S. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.60 · Cited by 84
Research works printed but not linked: 37
- Cordani, 2016, Mutant p53 proteins alter cancer cell secretome and tumour microenvironment: involvement in cancer invasion and metastasis, Cancer Lett, 376, 303, 10.1016/j.canlet.2016.03.046 · DOI
- Kandoth, 2013, Mutational landscape and significance across 12 major cancer types, Nature, 502, 333, 10.1038/nature12634 · DOI · Paper page
- Bisio, 2014, TP53 mutants in the tower of babel of cancer progression, Hum Mutat, 35, 10.1002/humu.22514 · DOI
- Jackson, 2013, The mutant p53 mouse as a pre-clinical model, Oncogene, 32, 4325, 10.1038/onc.2012.610 · DOI
- Kaar, 2010, Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding, Protein Sci, 19, 2267, 10.1002/pro.507 · DOI · Paper page
- Demma, 2010, SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain, restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of HDM2-mediated ubiquitination of wild-type p53, J Biol Chem, 285, 10198, 10.1074/jbc.M109.083469 · DOI
- Rippin, 2002, Characterization of the p53-rescue drug CP-31398 in vitro and in living cells, Oncogene, 21, 2119, 10.1038/sj.onc.1205362 · DOI · Paper page
- Zache, 2008, Mutant p53 targeting by the low molecular weight compound STIMA-1, Mol Oncol, 2, 70, 10.1016/j.molonc.2008.02.004 · DOI · Paper page
- Bykov, 2005, Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs, J Biol Chem, 280, 30384, 10.1074/jbc.M501664200 · DOI · Paper page
- Jung, 2016, Suppression of gain-of-function mutant p53 with metabolic inhibitors reduces tumor growth in vivo, Oncotarget, 7, 77664, 10.18632/oncotarget.12758 · DOI
- Rökaeus, 2010, PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73, Oncogene, 29, 6442, 10.1038/onc.2010.382 · DOI
- Bykov, 2014, Mutant p53 reactivation by small molecules makes its way to the clinic, FEBS Lett, 588, 2622, 10.1016/j.febslet.2014.04.017 · DOI · Paper page
- Liu, 2015, APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma, Gut, 64, 1506, 10.1136/gutjnl-2015-309770 · DOI
- Supiot, 2008, PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status, Radiother Oncol, 86, 407, 10.1016/j.radonc.2008.01.001 · DOI
- The Cancer Genome Atlas Research Network, 2011, Integrated genomic analysis of ovarian carcinoma, Nature, 474, 609, 10.1038/nature10166 · DOI · Paper page
- Basu, 2016, Pisarro: a phase 1b study of APR-246 with carboplatin and pegylated liposomal doxorubicin (PLD) in relapsed platinum-sensitive high grade serous ovarian cancer, Annal Oncol, 27, 386
- Salim, 2016, COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo, Oncotarget, 7, 41363, 10.18632/oncotarget.9133 · DOI · Paper page
- Puca, 2011, Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs, Cell Cycle, 10, 1679, 10.4161/cc.10.10.15642 · DOI
- Garufi, 2014, Degradation of mutant p53H175 protein by Zn(II) through autophagy, Cell Death Dis, 5, e1271, 10.1038/cddis.2014.217 · DOI
- Blanden, 2015, Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore, Mol Pharmacol, 87, 825, 10.1124/mol.114.097550 · DOI · Paper page
- Nelson, 2017, The essential medicinal chemistry of curcumin, J Med Chem, 60, 1620, 10.1021/acs.jmedchem.6b00975 · DOI · Paper page
- Lu, 2008, Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73, Cancer Biol Ther, 7, 2039, 10.4161/cbt.7.12.7461 · DOI
- Hong, 2014, Prodigiosin rescues deficient p53 signaling and antitumour effects via upregulating p73 and disrupting its interaction with mutant p53, Cancer Res, 74, 1153, 10.1158/0008-5472.CAN-13-0955 · DOI
- Mohell, 2015, APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells, Cell Death Dis, 6, e1794, 10.1038/cddis.2015.143 · DOI · Paper page
- Deben, 2016, APR-246 (PRIMA-1MET) strongly synergizes with AZD 2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines, Cancer Lett, 375, 313, 10.1016/j.canlet.2016.03.017 · DOI
- Yang-Hartwich, 2015, p53 protein aggregation promotes platinum resistance in ovarian cancer, Oncogene, 34, 3605, 10.1038/onc.2014.296 · DOI
- Xu, 2011, Gain of function of mutant p53 by co-aggregation with multiple tumor suppressors, Nat Chem Biol, 7, 285, 10.1038/nchembio.546 · DOI · Paper page
- Alexandrova, 2015, Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment, Nature, 523, 352, 10.1038/nature14430 · DOI · Paper page
- Wang, 2016, Hsp90 inhibitor ganetespib sensitizes non-small cell lung cancer to radiation but has variable effects with chemoradiation, Clin Cancer Res, 22, 5876, 10.1158/1078-0432.CCR-15-2190 · doi:10.1158/1078-0432.ccr-15-2190
- Ramalingam, 2015, A randomized phase 2 study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second line non-small-cell lung cancer (GALAXY-1), Ann Oncol, 26, 1741, 10.1093/annonc/mdv220 · DOI
- Kumar, 2011, Kevetrin activates p53, enhances expression of p21 induces cell cycle arrest and apoptosis in a human cancer cell line, Cancer Res, 71
- Kumar, 2017, Kevetrin induces p53-dependent and independent cell cycle arrest and apoptosis in ovarian cancer cell lines representing heterogeneous histologies, Cancer Res, 77
- Tamborero, 2013, Comprehensive identification of mutational cancer driver genes across 12 tumour types, Sci Rep, 3, 2650, 10.1038/srep02650 · DOI · Paper page
- Malkin, 2011, Li-Fraumeni syndrome, Genes Cancer, 2, 475, 10.1177/1947601911413466 · DOI · Paper page
- Purvis, 2012, p53 dynamics control cell fate, Science, 336, 1440, 10.1126/science.1218351 · DOI · Paper page
- Quartuccio, 2015, Mutant p53 expression in fallopian tube epithelium drives cell migration, Int J Cancer, 137, 1528, 10.1002/ijc.29528 · DOI
- Wu, 2013, Type I to Type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer, Am J Pathol, 182, 1391, 10.1016/j.ajpath.2012.12.031 · DOI
Cited by
Targeting p53 for the treatment of cancer
Duffy, M. J., Synnott, N. C., O’Grady, S., & Crown, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.005 · Cited by 349
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Green, J. A., Von Euler, M., & Abrahmsen, L. B.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 29
- Issue
- 5
- Pages
- 1325-1328
- ISSN
- 0923-7534
- Cited by
- 9
- References
- 8
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 616 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Restoration of conformation of mutant p53. https://app.cochat.ai/papers/10.1093/annonc/mdy057
- The paper
- Green, J. A., Von Euler, M., & Abrahmsen, L. B. (2018). Restoration of conformation of mutant p53. Annals of Oncology. https://doi.org/10.1093/annonc/mdy057
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.